Hematopoietic Stem Cell Transplantation for Hemoglobinopathies: Current Practice and Emerging Trends

Author(s):
Smiers, F.J.; Krishnamurti, L.; Lucarelli, G.
Published
2010
Publication type
Article / Letter to editor

Abstract

Despite improvements in the management of thalassemia major and sickle cell disease, treatment complications are frequent and life expectancy remains diminished for these patients. Hematopoietic stem cell transplantation (HSCT) is the only curative option currently available. Existing results for HSCT in patients with hemoglobinopathy are excellent and still improving. New conditioning regimens are being used to reduce treatment-related toxicity and new donor pools accessed to increase the number of patients who can undergo HSCT.

Hematopoietic stem cell transplantation HSCT Hemoglobinopathies bone-marrow-transplantation beta-thalassemia major cord blood transplantation iron-chelation-therapy versus-host-disease ineffective erythropoiesis transcranial doppler nonmalignant disorders hydroxyurea therapy fetal-hemoglobin
Date issued
2010-02-28
Language
English
Is part of
Pediatric Clinics of North America (2010), Vol. 57, no. 1, p. 181
hdl
1887/108837